Multiple Myeloma: all 3,712 studies
Page 30 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01503242Phase 1
- Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance TherapyWithdrawnNCT01501370Phase 2
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01497093Phase 1
- Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory MyelomaCompletedNCT01495351Phase 1
- Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaWithdrawnNCT01492881Phase 2
- Music Therapy on Nausea and Pain for Autologous Stem CellCompletedNCT01487031Not applicable
- A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01485835Phase 1
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- ACVDL Treatment for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01481194Phase 2
- Providing Access to Cord Blood Units for TransplantsWithdrawnNCT01479582Phase 2
- A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor CancersCompletedNCT01476137Phase 1
- Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in VitroCompletedNCT01472627
- A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaTerminatedNCT01470131Phase 3
- A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple MyelomaCompletedNCT01464112Phase 1
- A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01464034Phase 1/2
- Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationCompletedNCT01460420Phase 1/2
- A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01456689Phase 1
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic ProfileCompletedNCT01454297
- Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
- Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple MyelomaCompletedNCT01450215Phase 2
- A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple MyelomaWithdrawnNCT01445587Phase 2
- Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
- Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple MyelomaCompletedNCT01440556
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
- A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01432353Phase 1
- Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second LineCompletedNCT01430546
- Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT01428492Phase 1
- Pseudohyponatremia of Multiple Myeloma is True HyponatremiaStatus unknownNCT01425606
- Clinical Evaluation of the Serum Free Light Chain AnalysisStatus unknownNCT01423344
- Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple MyelomaTerminatedNCT01421927Phase 1
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
- Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic MalignanciesTerminatedNCT01416428Phase 1/2
- Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell TransplantCompletedNCT01416246Not applicable
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesCompletedNCT01413568Phase 1/2
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple MyelomaCompletedNCT01410981
- Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple MyelomaWithdrawnNCT01410929Phase 4
- Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory DiseaseApproved for marketingNCT01410500
- SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)CompletedNCT01402687
- Cyclophosphamide and Pulse Dexamethasone With Rapamycin or HydroxychloroquineCompletedNCT01396200Early Phase 1
- Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic PatientsCompletedNCT01394640
- Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)CompletedNCT01394354Phase 1/2
- Protocol to Obtain Blood and Bone Marrow Samples for Myeloma ResearchTerminatedNCT01382615
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
- Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance ImagingStatus unknownNCT01374412
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
- A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple MyelomaCompletedNCT01371227Phase 1
- Two Cycles of PAD Combination by AHCT in MMCompletedNCT01370434Phase 2
- Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing TreatmentsCompletedNCT01365559Phase 1/2
- Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
- Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving PlerixaforCompletedNCT01362972
- Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01359657Phase 1
- Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)CompletedNCT01352338Phase 1/2
- Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma PatientsCompletedNCT01346787Phase 2
- Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation CyclophosphamideCompletedNCT01342289Phase 1
- THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)CompletedNCT01341262Phase 2
- Clinical And Economic Impact Of Upfront Plerixafor In Autologous TransplantationCompletedNCT01339572Phase 2
- Study in Patients With Untreated Multiple Myeloma and Renal InsufficiencyCompletedNCT01337752Phase 2
- Phase II Study of Simvastatin for Relapsed/Refractory MyelomaWithdrawnNCT01332617Phase 2
- Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaCompletedNCT01330173Phase 1
- SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple MyelomaWithdrawnNCT01329289Phase 2
- Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell LeukemiaStatus unknownNCT01328236Phase 2
- Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)Status unknownNCT01325896Phase 2
- Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple MyelomaCompletedNCT01323751Phase 1/2
- A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) PatientsStatus unknownNCT01314625
- A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple MyelomaTerminatedNCT01309412Phase 1
- Imaging Young Myeloma (IMAgerie JEune Myélome)CompletedNCT01309334Phase 3
- Study of BHQ880 in Patients With High Risk Smoldering Multiple MyelomaCompletedNCT01302886Phase 2
- Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01301807Phase 1
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT01297764Phase 1/2
- Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple MyelomaCompletedNCT01296503Phase 3
- Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131CompletedNCT01296204Phase 1
- Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCTCompletedNCT01286675Early Phase 1
- Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell TransplantationCompletedNCT01283776Phase 2
- A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple MyelomaCompletedNCT01274403Phase 2
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple MyelomaCompletedNCT01272466Phase 1/2
- Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure PatientsCompletedNCT01270932Phase 2
- Role of BCL-B in Multiple MyelomaCompletedNCT01270009
- Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma PatientsWithdrawnNCT01269203Phase 2
- Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.CompletedNCT01268774
- A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT01266811Phase 3
- Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic TransplantCompletedNCT01264315Phase 2
- Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 StudyStatus unknownNCT01255527Phase 1/2
- Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaCompletedNCT01255514Phase 2
- RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT01251172Phase 2
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple MyelomaStatus unknownNCT01249690Phase 4
- A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 1
- Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaCompletedNCT01242930Phase 2
- A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any ProcedureCompletedNCT01241396
- Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneCompletedNCT01237249Phase 2
- IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor EverolimusWithdrawnNCT01234974Phase 2
- Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple MyelomaCompletedNCT01234129
- Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple MyelomaCompletedNCT01233895Phase 1
- A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor MalignanciesCompletedNCT01232712Phase 1/2
- PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With MyelomaCompletedNCT01220375Phase 2
- A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple MyelomaCompletedNCT01219010Phase 1
- Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapseCompletedNCT01217203Phase 1
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01208766Phase 3
- Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2